2023 World Conference on Lung Cancer (Posters)-EP12.01. Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia

EP12.01. Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the response of patients with newly diagnosed EGFR mutation non-small cell lung cancer (NSCLC) in a tertiary referral cancer center in Jakarta, Indonesia. The study was conducted as a prospective cohort study from 2022. The researchers collected demographic data, smoking history, histologic subtype, EGFR mutation status, ALK rearrangement status, PD-L1 expression status, treatment history, and treatment response of the patients.<br /><br />The results showed that the majority of the patients with EGFR mutation NSCLC were females, had adenocarcinoma histologic subtype, were in the metastatic stage, and had point mutation exon 21 or deletion exon 19. Most of the subjects did not show progression with EGFR tyrosine kinase inhibitor (TKI) targeted therapy. <br /><br />The study also evaluated the treatment response based on RECIST 1.1 after 6 months of treatment. The results showed that 54% of the patients received TKIs as their therapy and had a response, while 11% received chemotherapy and TKIs and had a response. 23% of the patients received chemotherapy alone and had a response. 12% of the patients did not receive any therapy.<br /><br />In conclusion, the study found that EGFR mutated NSCLC patients in the tertiary referral cancer center in Jakarta, Indonesia, had a favorable response to EGFR TKI targeted therapy. These findings highlight the importance of genotype-guided treatment for NSCLC patients with EGFR mutations.

Asset Subtitle

Devi Amelia

Meta Tag

Speaker Devi Amelia

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

EGFR mutation

NSCLC

tertiary referral cancer center

Jakarta, Indonesia

prospective cohort study

treatment response

metastatic stage

EGFR tyrosine kinase inhibitor

chemotherapy

genotype-guided treatment